ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer
source: pixabay.com

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

Over 50% of non-small cell lung cancer patients (NSCLC) will experience a recurrence after surgery. The cancer recurs even after adjuvant chemotherapy after major surgery. ALINA’s data show that Alecensa…

Continue Reading ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer